<div><div></div><div><span><p><strong><span>On December 6, 2025, Nurix Therapeutics, Inc. presented new clinical data on bexobrutideg at the ASH Annual Meeting.</span></strong></p><span> </span><p><strong><span>Key Highlights:</span></strong></p><span> </span><ul><li><span>Phase 1a study showed an 83% ORR in CLL/SLL patients.</span></li><li><span>600 mg dose in Phase 1b showed higher ORR than 200 mg.</span></li><li><span>Bexobrutideg was well tolerated with no dose-limiting toxicities.</span></li><li><span>75% ORR observed in Waldenström macroglobulinemia patients.</span></li><li><span>Data supports advancing 600 mg dose in pivotal trials.</span></li></ul><p><span>Original SEC Filing: </span>Nurix Therapeutics, Inc. [ NRIX ] - 8-K - Dec. 09, 2025</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

NRIX

<p>Nurix Therapeutics presented new clinical data on bexobrutideg at the ASH Annual Meeting, showing promising results in Phase 1a and 1b studies. The 600 mg dose demonstrated higher ORR and was well tolerated, with no dose-limiting toxicities. The data supports advancing the 600 mg dose in pivotal trials.</p>

Nurix Therapeutics Presents New Clinical Data at ASH Annual Meeting